Zydus Lifesciences Limited, a active public limited company, was established on 15 May 1995 in Ahmedabad, Gujarat, India. Engaging in drug formulation & development within the manufacturing sector, it holds CIN: L24230GJ1995PLC025878. Registered under ROC Roc Ahmedabad. it is listed on BSE: 532321 and NSE: CADILAHC. It has an authorized capital of ₹172.50 Cr and a paid-up capital of ₹100.62 Cr.
Formerly known as Cadila Healthcare Private Limited. It upholds a compliant status. In 2023, it reported revenue of ₹9,280.00 Cr and a net worth of ₹13,639.42 Cr. Employing 13,762 professional, Its leadership includes Ganesh Narayan Nayak (Whole-Time Director), Shelina Pranav Parikh (Director), Pankaj Ramanbhai Patel (Director). Past directors included Dharmishta Narendraprasad Raval, Upenkumar Shah Harshadlal, Pranlal Bhogilal Patel. It holds ₹1,500.00 Cr open charges and ₹3,001.83 Cr settled loans. Its latest AGM occurred on 12 August 2025, with the balance sheet filed on 31 March 2025. It is based at Zydus Corporate Park,Scheme No. 63, Survey No. 536 Khoraj(Gandhinagar),Nr. Vaishnodevi Circ, Le,, Ahmedabad, Gujarat, 382481.
L24230GJ1995PLC025878
025878
15 May 1995
₹172.50 Cr
₹100.62 Cr
Roc Ahmedabad
Listed (BSE: 532321, NSE: CADILAHC)
Active
Explore comprehensive insights into Zydus Lifesciences Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Ganesh Narayan Nayak | Whole-Time Director | 12 Jul 2017 | Current |
| Shelina Pranav Parikh | Director | 17 May 2024 | Current |
| Pankaj Ramanbhai Patel | Director | 15 May 1995 | Current |
| Sharvil Pankajbhai Patel | Managing Director | 01 Aug 1997 | Current |
| Mukesh Mangalbhai Patel | Director | 01 Aug 1997 | Current |
| Monappa Arun Akhil | Director | 29 Nov 2022 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Additional Director | 30 Jul 2014 | Past |
| Pramod Abcsdd | Company Secretary | 07 Feb 2019 | Past |
| Pramod Abcsdd | Director | 12 Jan 2011 | Past |
| Pramod Abcsdd | Additional Director | 19 Jul 2011 | Past |
| Pramod Abcsdd | Person Incharge | 05 Mar 2014 | Past |
| Pramod Abcsdd | Additional Director | 08 Aug 2024 | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Zydus Lifesciences Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 13.72% increase. The company also saw a substantial improvement in profitability, with a 78.25% increase in profit. The company's net worth moved up by a moderate rise of 3.01%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
In 2024, Zydus Lifesciences had a promoter holding of 74.98% and a public holding of 25.01%. The company had 16 Subsidiaries and 3 Joint Ventures. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Reveal ownership structures and financial performance - Get instant access now!
₹15,000,000,000.00
₹30,018,316,836.00
| Date | Lender | Amount | Status |
|---|---|---|---|
| 21 Dec 2012 | Others | ₹1,500.00 Cr | Open |
| 24 Dec 2015 | Citi Bank N.A. | ₹225.00 Cr | Satisfied |
| 07 Aug 2014 | Citi Bank N.A. | ₹93.00 Cr | Satisfied |
| 28 May 2014 | Others | ₹120.40 Cr | Satisfied |
| 21 Nov 2013 | Citi Bank N.A. | ₹94.50 Cr | Satisfied |
Explore comprehensive loan charge details -
Zydus Lifesciences has a workforce of 13762 employees as of Jan 16, 2025. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Gain comprehensive insights into the Deals and Valuation data of Zydus Lifesciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Zydus Lifesciences's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
The activity Tushar Dhansukh Shroff was appointed as a Cfo was appointed as a Cfo on 16 Sep 2025 & has been associated with this company since 2 months 10 days . was completed.
Zydus Lifesciences Limited last Annual general meeting of members was held on 12 Aug 2025 as per latest MCA records. was recorded as a recent event.
Progress on Zydus Lifesciences Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Ahmedabad. was documented.
Progress on Shelina Pranav Parikh was appointed as a Director was appointed as a Director on 17 May 2024 & has been associated with this company since 1 year 6 months . was documented.
Progress on Monappa Arun Akhil was appointed as a Director was appointed as a Director on 29 Nov 2022 & has been associated with this company since 2 years 11 months . was documented.
The activity Upasana Konidela was appointed as a Director was appointed as a Director on 29 Nov 2022 & has been associated with this company since 2 years 11 months . was completed.
Zydus Lifesciences Ltd., the pharmaceutical company, announced its equity share buyback on Tuesday. Check buy-back dates, price and other Details..
The drug will be manufactured at the group’s manufacturing premises Zydus Lifesciences has launched Relugolix under the brand name, Rexigo. This is the first and only oral once-a-day therapy for testo.
The CIN of Zydus Lifesciences Limited is L24230GJ1995PLC025878.
Zydus Lifesciences Limited is headquartered at Zydus Corporate Park,Scheme No. 63, Survey No. 536 Khoraj(Gandhinagar),Nr. Vaishnodevi Circ, Le,, Ahmedabad, Gujarat, 382481.
Zydus Lifesciences Limited was incorporated on 15 May 1995.
The current directors of Zydus Lifesciences Limited are
The primary industry of Zydus Lifesciences Limited is Manufacturing.
Zydus Lifesciences Limited is listed. It is listed on BSE: 532321 and NSE: CADILAHC.
The authorized capital of Zydus Lifesciences Limited is ₹172.50 Cr, and the paid-up capital is ₹100.62 Cr.
The compliance status of Zydus Lifesciences Limited is Compliant.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX